We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Ustekinumab as a Treatment for Ixekizumab-Associated New-Onset Crohn's Disease in a Patient with Psoriasis.
- Authors
Tan, Justin Ryan L.; Alba, Willy S.
- Abstract
Interleukin-17 inhibitors are effective treatments for plaque psoriasis. However, these medications have been linked to the development of new-onset inflammatory bowel disease (IBD) and the worsening of existing IBD in some patients. This case report describes a patient with plaque psoriasis who developed new-onset Crohn's disease after treatment with ixekizumab, an interleukin-17A inhibitor. He was then transitioned to ustekinumab, which resulted in successful remission of both psoriasis and Crohn's disease. This case highlights the potential for ustekinumab to be an effective rescue treatment for psoriasis patients with new-onset IBD triggered by medications.
- Subjects
THERAPEUTIC use of monoclonal antibodies; PSORIASIS; INTERLEUKINS; CROHN'S disease; INFLAMMATORY bowel diseases; DRUG side effects; DISEASE remission; CHEMICAL inhibitors; DISEASE complications
- Publication
ACG Case Reports Journal, 2024, Vol 11, Issue 2, p1
- ISSN
2326-3253
- Publication type
Article
- DOI
10.14309/crj.0000000000001266